India, June 13 -- image credit- freepik

Mumbai-based Ipca Laboratories and Bhami's Research Laboratory (BRL) have announced a definitive global licensing agreement granting Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialisation of multiple monoclonal antibody products targeting oncology and inflammatory diseases.

BRL will receive defined milestone fee pertaining to the Technology Transfer, and Royalty on net sales upon commercialisation of the product. BRL is headquartered in Mangalore, with core expertise in protein and peptide drug delivery.

Pranay Godha, MD & CEO, Ipca Laboratories said, "By pairing Ipca's established science with BRL's Novel Formulation...